2 / 53
• Incidence 2–7% of patients with
advanced NSCLC
• Age: 50–60 years
• Light/never smoker
• Brain metastases (>50%) during
the course of the disease
• Predominantly
adenocarcinoma histology
(signet cell)
• Testing
ALK
+ NSCLC
De Castro, et al. Clin Transl Oncol 2011; Gridelli, et al. Cancer Treat Rev 2014
Shaw, et al. Cin Cancer Res 2011; Dearden, et al. Ann Oncol 2013
Hallberg, et al. Nat Rev Cancer 2013; Rikova, et al. Cell 2007; Soda, et al. Nature 2007
Perez, et al. Lung Cancer 2014; Shaw, et al. WCLC 2015; Ou, et al. ASCO 2015; Mok, et al. ASCO 2015
ALK = anaplastic lymphoma kinase
NSCLC = non-small-cell lung cancer